These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
274 related articles for article (PubMed ID: 26607467)
1. Favorable effects of vildagliptin on metabolic and cognitive dysfunctions in streptozotocin-induced diabetic rats. El Batsh MM; El Batch MM; Shafik NM; Younos IH Eur J Pharmacol; 2015 Dec; 769():297-305. PubMed ID: 26607467 [TBL] [Abstract][Full Text] [Related]
2. Vildagliptin selectively ameliorates GLP-1, GLUT4, SREBP-1c mRNA levels and stimulates β-cell proliferation resulting in improved glucose homeostasis in rats with streptozotocin-induced diabetes. Akarte AS; Srinivasan BP; Gandhi S J Diabetes Complications; 2012; 26(4):266-74. PubMed ID: 22626875 [TBL] [Abstract][Full Text] [Related]
3. Neuroprotective effects of vildagliptin in rat rotenone Parkinson's disease model: role of RAGE-NFκB and Nrf2-antioxidant signaling pathways. Abdelsalam RM; Safar MM J Neurochem; 2015 Jun; 133(5):700-7. PubMed ID: 25752913 [TBL] [Abstract][Full Text] [Related]
4. Vildagliptin ameliorates oxidative stress and pancreatic beta cell destruction in type 1 diabetic rats. Ávila Dde L; Araújo GR; Silva M; Miranda PH; Diniz MF; Pedrosa ML; Silva ME; de Lima WG; Costa DC Arch Med Res; 2013 Apr; 44(3):194-202. PubMed ID: 23523961 [TBL] [Abstract][Full Text] [Related]
5. SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats. Sa-Nguanmoo P; Tanajak P; Kerdphoo S; Jaiwongkam T; Pratchayasakul W; Chattipakorn N; Chattipakorn SC Toxicol Appl Pharmacol; 2017 Oct; 333():43-50. PubMed ID: 28807765 [TBL] [Abstract][Full Text] [Related]
7. Combination of Vildagliptin and Pioglitazone in Experimental Type 2 Diabetes in Male Rats. Refaat R; Sakr A; Salama M; El Sarha A Drug Dev Res; 2016 Sep; 77(6):300-9. PubMed ID: 27520857 [TBL] [Abstract][Full Text] [Related]
8. Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (Vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats. Jin HY; Liu WJ; Park JH; Baek HS; Park TS Arch Med Res; 2009 Oct; 40(7):536-44. PubMed ID: 20082866 [TBL] [Abstract][Full Text] [Related]
9. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes. Kodera R; Shikata K; Takatsuka T; Oda K; Miyamoto S; Kajitani N; Hirota D; Ono T; Usui HK; Makino H Biochem Biophys Res Commun; 2014 Jan; 443(3):828-33. PubMed ID: 24342619 [TBL] [Abstract][Full Text] [Related]
10. The protective effect of vildagliptin in chronic experimental cyclosporine A-induced hepatotoxicity. El-Sherbeeny NA; Nader MA Can J Physiol Pharmacol; 2016 Mar; 94(3):251-6. PubMed ID: 26632647 [TBL] [Abstract][Full Text] [Related]
11. Chronic DPP-IV inhibition with PKF-275-055 attenuates inflammation and improves gene expressions responsible for insulin secretion in streptozotocin induced diabetic rats. Akarte AS; Srinivasan BP; Gandhi S; Sole S Eur J Pharm Sci; 2012 Sep; 47(2):456-63. PubMed ID: 22800967 [TBL] [Abstract][Full Text] [Related]
13. Dual therapy of vildagliptin and telmisartan on diabetic nephropathy in experimentally induced type 2 diabetes mellitus rats. Sharma AK; Kanawat DS; Mishra A; Dhakad PK; Sharma P; Srivastava V; Joshi S; Joshi M; Raikwar SK; Kurmi MK; Srinivasan BP J Renin Angiotensin Aldosterone Syst; 2014 Dec; 15(4):410-8. PubMed ID: 23396552 [TBL] [Abstract][Full Text] [Related]
14. Vildagliptin increases butyrate-producing bacteria in the gut of diabetic rats. Zhang Q; Xiao X; Li M; Yu M; Ping F; Zheng J; Wang T; Wang X PLoS One; 2017; 12(10):e0184735. PubMed ID: 29036231 [TBL] [Abstract][Full Text] [Related]
15. Relationships between the islets blood flow, nitric oxide, insulin, and cytosolic calcium in rat pancreatic islets: effects of DPP-IV inhibitor vildagliptin. Akarte AS; Srinivasan BP; Gandhi S Eur J Pharm Sci; 2012 Apr; 45(5):546-51. PubMed ID: 22155545 [TBL] [Abstract][Full Text] [Related]
16. Beneficial effects of PKF275-055, a novel, selective, orally bioavailable, long-acting dipeptidyl peptidase IV inhibitor in streptozotocin-induced diabetic peripheral neuropathy. Bianchi R; Cervellini I; Porretta-Serapiglia C; Oggioni N; Burkey B; Ghezzi P; Cavaletti G; Lauria G J Pharmacol Exp Ther; 2012 Jan; 340(1):64-72. PubMed ID: 21984837 [TBL] [Abstract][Full Text] [Related]
17. Effects of N-adamantyl-4-methylthiazol-2-amine on hyperglycemia, hyperlipidemia and oxidative stress in streptozotocin-induced diabetic rats. Yang SJ; Je Lee W; Kim EA; Dal Nam K; Hahn HG; Young Choi S; Cho SW Eur J Pharmacol; 2014 Aug; 736():26-34. PubMed ID: 24797782 [TBL] [Abstract][Full Text] [Related]
18. Neuroprotective effect of selective DPP-4 inhibitor in experimental vascular dementia. Jain S; Sharma B Physiol Behav; 2015 Dec; 152(Pt A):182-93. PubMed ID: 26382939 [TBL] [Abstract][Full Text] [Related]
19. Effects of 20-hydroxyecdysone on improving memory deficits in streptozotocin-induced type 1 diabetes mellitus in rat. Xia X; Zhang Q; Liu R; Wang Z; Tang N; Liu F; Huang G; Jiang X; Gui G; Wang L; Sun X Eur J Pharmacol; 2014 Oct; 740():45-52. PubMed ID: 24997424 [TBL] [Abstract][Full Text] [Related]
20. BAY 11-7082 ameliorates diabetic nephropathy by attenuating hyperglycemia-mediated oxidative stress and renal inflammation via NF-κB pathway. Kolati SR; Kasala ER; Bodduluru LN; Mahareddy JR; Uppulapu SK; Gogoi R; Barua CC; Lahkar M Environ Toxicol Pharmacol; 2015 Mar; 39(2):690-9. PubMed ID: 25704036 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]